Introduction
Osteoarthritis (OA) is a chronic, painful arthritis that can lead to reduced functioning and substantial disability in affected individuals. It is estimated that 242 million people worldwide are affected with OA of the hip or knee. 1 The prevalence is increasing with an ageing population, along with rising risk factors such as obesity. 2 The pathogenesis of OA is complex and is thought to develop as a result of the interplay between mechanical, genetic, metabolic and inflammatory mechanisms. 3 Management of OA symptoms involves pharmacological and non-pharmacological strategies, with joint replacement considered in symptomrefractory disease. Analgesia remains the mainstay of pharmacological treatment for symptomatic OA, including paracetamol, topical and oral nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid medications. However, benefits from paracetamol and opioids are limited, and NSAIDs and opioids are not suitable for many patients given their side-effect profile. 4 Intra-articular therapies such as corticosteroids are also commonly used, though often with short-term benefits.
Given the central role of pain in the clinical syndrome of OA, new therapeutics have targeted peripheral nociceptive pain pathways. Diseasemodifying osteoarthritis drugs (DMOADs) are a putative class of agents which aim to act on the key tissues involved in OA to prevent structural progression and therefore improve symptoms. Currently, no DMOADs have been licensed for use but a number of potential therapies are under investigation.
This narrative review will provide an overview for clinicians of recent advances in knowledge on the use of existing pharmacological therapies and discuss novel treatments currently under an advanced stage of investigation (at least in phase II trials) for the treatment of OA. The therapies discussed have primarily been investigated for the treatment of knee OA, with some having been trialled in hand OA.
Scope of this review
Although this was a narrative review, we based it on a PubMed search for publications and a review of relevant meeting abstracts on pharmacotherapy trials in OA reported in 2017 and 2018. Only pharmacological therapies in at least phase II development for primary OA were selected; exercise, therapies marketed as devices (such as hyaluronans), nutraceuticals (such as glucosamine) and other non-pharmacological interventions were not included. Where relevant, older studies were referenced to give background detail on the candidate therapy.
Update on existing therapies
Colchicine. While colchicine is not currently recommended for treatment of OA, it is commonly used for the treatment of gout and pseudogout. Basic calcium phosphate (BCP) crystals have been detected in synovial fluid in OA, with hydroxyapatite the most common form found in OA joints (detected in the cartilage of up to 100% of affected joints at the time of joint replacement). 5 Positive correlations have been reported between synovial fluid BCP crystal levels and radiographic OA severity. 6 BCP crystals activate the inflammasome including NOD-, LRR-and pyrin domain-containing 3 (NLRP3) which increase interleukin (IL)-1β expression, the levels of which also correlate with OA severity. 7, 8 Colchicine was recently trialled in OA as it is thought to block IL-1β release by inhibiting NLRP3. 9 The three previous small trials found symptomatic improvement with colchicine in OA knee patients. [10] [11] [12] A more recent doubleblind, placebo-controlled, randomized trial compared colchicine 500 µg twice daily with placebo over 16 weeks in 109 patients with knee OA. The study did not achieve its primary endpoint of a significant improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score at week 16. 13 Although colchicine is therefore unlikely to provide a new OA therapy, understanding the place of treating nonurate crystal disease requires future consideration.
Hydroxychloroquine.
Hydroxychloroquine has been used in clinical practice in patients with inflammatory hand OA with anecdotal evidence of benefit, in part because of its effectiveness in treating rheumatoid arthritis (RA) synovitis and an acceptable safety profile. 14, 15 It has a variety of immunomodulatory effects and was considered to potentially treat OA due to its inhibitory action on Toll-like receptor (TLR) signalling, 16 as TLRs are upregulated in OA cartilage and thought to stimulate cartilage breakdown via proinflammatory pathways. 17, 18 In addition, there is evidence of synovitis in hand OA. 19, 20 Previous small pilot studies suggested improvements in symptoms after hydroxychloroquine treatment. 21, 22 A large randomized, double-blind, placebo-controlled clinical trial analysed 248 patients over a 12 month period. 23 Patients with moderate to severe hand pain were randomized to hydroxychloroquine or placebo, in addition to their usual analgesic medication. The study did not demonstrate a significant reduction in hand pain with additional hydroxychloroquine compared with placebo at 6 months, thereby not achieving primary endpoint. There was also no significant difference in radiographic progression between treatment groups at 12 months. In a subset of patients, stratification for (commonly found) ultrasounddetected synovitis did not change the study results. Another randomized controlled trial comparing hydroxychloroquine 400 mg with placebo in 196 patients with hand OA (and not on concomitant NSAID or corticosteroid treatment) also did not detect a significant difference in pain scores after 24 weeks of treatment. 24 Tumour necrosis factor inhibitors. There is evidence that tumour necrosis factor alpha (TNF-α) is implicated in OA pathogenesis; 25 however, previous studies have not demonstrated adalimumab to be effective compared with placebo in reducing symptoms in hand OA. 26, 27 More recently, the HUMOR trial compared subcutaneous adalimumab 40 mg every other week with placebo over 12 weeks in a crossover trial of patients with erosive hand OA and evidence of magnetic resonance imaging (MRI)-defined synovitis. 28 A total of 43 patients were randomized and there was an 8 week washout period before treatment groups crossed over. No significant difference was detected in visual analogue scale (VAS) scores for pain between the treatment groups. No significant differences were detected for any secondary outcomes including change in MRI-detected synovitis and bone marrow lesions.
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Etanercept has recently been studied in a 1 year, double-blind, randomized, placebo-controlled, multicentre trial of 90 patients with symptomatic erosive inflammatory hand OA. The study did not achieve its primary endpoint of a significant improvement in VAS pain at 24 weeks with etanercept 50 mg weekly. 29 In addition, no significant treatment reduction in ultrasonographic or MRI-detected synovitis was seen after 1 year. The study also detected a significant reduction in MRI-detected bone marrow lesions in the interphalangeal joints of one hand after 1 year with etanercept; however, this was in a very small subgroup (n = 10 in each treatment group).
Injectable corticosteroids. Intra-articular corticosteroids are commonly used for OA, with most trials focusing on the knee. While patients experience substantial improvement in pain scores, symptomatic improvement tends to be shortlived, with no associated benefit seen at 6 months. 30 A Cochrane review of 27 trials found an association with small-to-moderate improvement in function at up to 6 weeks, but no improvement beyond this timeframe. 31 It also found moderateto-large heterogeneity between trials.
Intra-articular triamcinolone acetonide extended release. Given the short-lived benefits of corticosteroid, FX006, a preparation of triamcinolone acetonide extended release (TA-ER) produced using microsphere technology, was trialled in patients with knee OA, with the aim of giving prolonged benefits. A phase IIa randomized, double-blind, controlled, dose-finding trial compared TA-ER at doses 10 mg, 40 mg and 60 mg with immediaterelease triamcinolone 40 mg in 228 patients with knee OA. 32 Patients were followed up for 12 weeks after single intra-articular knee injection. The results demonstrated a significant improvement in mean daily pain intensity scores with TA-ER 40 mg versus immediate-release triamcinolone 40 mg at weeks 5-10. In addition, all WOMAC subscale scores were superior in TA-ER 40 mg compared with immediate-release triamcinolone at 8 weeks. TA-ER 10 mg and 60 mg were not reported to be significantly superior to immediate-release triamcinolone 40 mg. TA-ER reported similar frequencies of adverse events (AEs) to immediate-release triamcinolone.
A further phase IIb study compared TA-ER with placebo in 306 patients with knee OA. The study failed to achieve its primary outcome of a significant improvement in average daily pain (ADP) intensity versus placebo at time point of 12 weeks; however, there were significant improvements in ADP intensity scores with TA-ER 32 mg versus placebo at weeks 1-11 and at week 13. 33 A more recent phase III, multicentre, double-blinded, randomized, controlled trial compared TA-ER (32 mg) with immediate-release triamcinolone (40 mg) and placebo in 484 patients with knee OA. 34 It achieved its primary endpoint of a significant improvement in ADP intensity compared with placebo at 12 weeks. There was no significant improvement in ADP intensity with TA-ER versus immediate-release triamcinolone at 12 weeks; however, the WOMAC pain, stiffness and physical function scores, and the Knee injury and Osteoarthritis Outcome Score (Quality of Life subdomain; KOOS-QoL) at 12 weeks significantly improved with TA-ER 32 mg compared with both placebo and immediate-release triamcinolone. The differences between the active comparator seen for the different outcome measures may well reflect a greater responsiveness for the diseasespecific, multi-item WOMAC tool over the ADP single item question. Given the significant improvement over placebo, TA-ER has been licensed by the United States Food and Drug Administration (US FDA) for managing OA-related knee pain. One further advantage of TA-ER's mechanism of action with slow intraarticular release, is reduced systemic exposure compared with immediate-release triamcinolone. 35 It has been demonstrated that TA-ER 32 mg gives less glycaemic disruption compared with standard triamcinolone 40 mg in patients with type 2 diabetes. 36 Intramuscular corticosteroid. While intraarticular corticosteroid injections are of shortterm benefit in hip OA, 37 a recent randomized, double-blind, trial compared intramuscular triamcinolone acetate 40 mg with placebo in patients with hip OA. 38 Intramuscular injections require less training and would be of potential benefit in primary care management of OA. Pain levels at rest and on walking using an 11-point numeric rating scale (NRS; 0-10, where 0 = no pain) and WOMAC pain levels were recorded at 2, 4, 6 and 12 weeks after injection. The results from 106 patients were analysed and demonstrated a significant reduction in NRS hip pain at rest in the triamcinolone group compared with the placebo control group at 2 weeks. This significant difference persisted for the whole 12 weeks of the trial period. No significant difference in pain on walking and WOMAC pain was demonstrated at 2 weeks. However, triamcinolone was significantly superior to placebo at reducing pain on walking at 4, 6 and 12 weeks. Triamcinolone was also significantly superior in reducing WOMAC pain, function, stiffness and total scores compared with placebo at weeks 4, 6 and 12. The magnitude of improvement in NRS pain at 2 weeks was reported as probably clinically relevant, but not for beyond that time point. In addition, only one of the three primary outcome measurements were achieved at 2 weeks.
Bisphosphonates. Subchondral bone pathology is integral to the OA process and a number of therapies used for osteoporosis have been explored as OA therapies. Strontium ranelate was studied in the SEKOIA trial, a randomized, double-blind, 3-year study involving 1683 patients with symptomatic primary knee OA and compared strontium 1 or 2 g/day with placebo. 39 The study demonstrated a significant reduction in joint space width degradation with both strontium doses compared with placebo. Results also showed a significant improvement in WOMAC total score and pain subscore at 2 g/day; however, a 14% annualized dropout rate highlights the complex issues of participant retention in long-term OA trials and handling missing data.
Bisphosphonates, related to their anti-osteoclastic actions, have also been trialled in OA, where their mechanism of action may have benefits on subchondral bone and cartilage. A meta-analysis of seven randomized, placebo-controlled trials did not show symptomatic improvement or reduction in radiographic OA progression with bisphosphonate therapy. 40 The analysis did suggest bisphosphonates may still have potential benefit in a subset of patients with high rates of subchondral bone turnover. Recent studies have recruited patients with subchondral bone abnormalities [patients with bone marrow lesions (BMLs)]. BMLs are commonly seen on MRI scans of OA knees and are associated with both pain and progressive cartilage loss. [41] [42] [43] [44] A double-blind, parallel-group, placebo-controlled trial of zoledronic acid (ZA) recruited 59 patients aged 50-80 years with knee pain and at least one BML on MRI. 45 Significant symptomatic benefit and a reduction in BMLs were reported at 6 months. The preliminary report from the larger follow-up, multicentre, randomized controlled trial, comparing onceyearly intravenous infusion of ZA 5 mg with placebo on knee pain and BML size over 24 months in 223 patients with knee OA, significant knee pain and MRI-detected BMLs has recently been presented. 46 However in this new trial, no significant difference in WOMAC pain score, WOMAC function score, or BML change was detected between treatment groups after 24 months.
Therapies in advanced trial development Intra-articular capsaicin. Transient receptor potential cation channel subfamily V member 1 (TRPV1) is a protein expressed on nociceptive nerve fibres (Aδ and C) and its activation leads to a prolonged refractory state known as desensitization 47 It is therefore an attractive target for potential analgesic medication. CNTX-4975 is a highly purified, synthetic trans-capsaicin with specific activity for TRPV1-containing pain nociceptors. It does not impact other sensory fibres such as touch or pressure and is the first intra-articular capsaicin preparation. 48 Previous evidence has supported topical capsaicin in relieving OA pain. 49 -52 A 24-week, randomized, double-blind, placebo-controlled, dose-ranging study demonstrated significant improvement in WOMAC A1 pain score (defined as how much pain a patient has when walking on a flat surface) at 12 and 24 weeks with a single dose CNTX-4975 1 mg knee injection in patients with moderately painful knee OA. 53 Data on AEs are limited currently but the most common treatment-emergent adverse event is reported to be arthralgia. 53 A phase III trial and a study examining efficacy of repeated doses of CNTX-4975 are currently in progress. 54, 55 Anti-nerve growth factor monoclonal antibodies. Nerve growth factor (NGF) is a neurotrophin with increased expression in OA and is thought to stimulate growth of nociceptive nerve fibres and expression of nociceptive cell surface receptors. 56 The joint capsule, ligaments, periosteum, menisci, subchondral bone and synovium are all highly innervated with nociceptive nerve fibres and potential sources of joint and knee pain in OA. 57 The peripheral nociceptive pathway therefore offers novel targets for analgesic agents.
Tanezumab is a monoclonal antibody strongly targeting NGF, thereby preventing it from binding its receptor with the overall aim of reducing pain. 58 Other anti-NGF biologics on trial include fasinumab and fulranumab, although development of fulranumab has now terminated. A meta-analysis of 9 studies with 10 randomized controlled trials enrolling 7665 patients compared tanezumab with placebo/active comparator in knee or hip OA. This Tanezumab has also been compared with NSAIDs (celecoxib 100 mg and naproxen 500 mg) and oxycodone 10-40 mg, with tanezumab monotherapy at 5 mg and 10 mg demonstrating superior efficacy to each of these drugs. 61, 62 Combined tanezumab and NSAID therapy also demonstrated superior analgesic efficacy compared with NSAID monotherapy but not tanezumab monotherapy. 62 A number of AEs have been reported with tanezumab, although rates of discontinuation due to these are low. 59 Tanezumab-treated patients are significantly more likely to experience paraesthesia, headaches, arthralgia, peripheral oedema, peripheral neuropathy, hypo-and hyper-aesthesia. Arthralgia was the most commonly reported side effect (8% of tanezumab-treated patients).
Lower doses of tanezumab are associated with fewer AEs. 59 Rapidly progressive OA (RPOA) is the most serious AE reported with tanezumab and fulranumab, with the risk of RPOA being doseresponsive. 63 It is a painful condition diagnosed radiographically by rapid joint space narrowing and severe progressive atrophic bone and has been reported in 1% of patients who received tanezumab. 64 In recent trials, tanezumab is used at a maximal 5 mg dose in patients with hip or knee OA as the risk appears lower and is outweighed by its potential therapeutic benefit. 65 The combination of tanezumab and NSAIDs appears to increase the risk of RPOA compared with tanezumab alone. 65 
Potential DMOADs
It should be possible to modify key structures or tissues within the OA joint; however, the challenges for DMOAD trials include: the very slow rate of cartilage loss in OA knees over time, the insensitivity of radiographic outcome measures resulting in the need for very large trials, and poor understanding of the relationship between structure and symptoms.
Sprifermin. Sprifermin (rhFGF18) is recombinant fibroblast growth factor 18 administered via intraarticular route and acts on FGFR3 receptors in cartilage. 66 Animal models of OA have shown that fibroblast growth factor 18 can stimulate cartilage growth by proliferation of chondrocytes and modulating extracellular matrix turnover. 67, 68 A 1 year, randomized, double-blind, placebocontrolled, proof-of-concept trial compared sprifermin doses of 10 μg, 30 μg, and 100 μg. 69 Patients were given two cycles of three onceweekly injections (weeks 0-2 and 13-15) of sprifermin or placebo. Of the 168 patients evaluated, sprifermin did not achieve its primary efficacy endpoint of significant reduction in central medial femorotibial compartment cartilage thickness loss at 6 or 12 months; however, sprifermin (at all doses) did achieve its prespecified secondary structural efficacy MRI endpoints, including a significant reductions in the loss of total femorotibial and lateral femorotibial cartilage thickness and reduced loss of radiographically evident lateral joint space width at 12 months.
A 5-year phase II, dose-ranging, randomized, placebo-controlled trial (FORWARD) is currently in progress. A total of 549 patients were randomized of which 18.4% (sprifermin) and 24.1% (placebo) discontinued the study within 3 years. Structural endpoints (cartilage thickness) were measured by quantitative MRI at the tibiofemoral joint. Preliminary results at 3 years demonstrate the expected (natural history) reduction in mean cartilage thickness from baseline to 3 years was significantly lower in patients on sprifermin 100 μg than placebo at the total femorotibial joint, and in the medial, lateral, central medial and central-lateral subregion. There was an initial increase in overall cartilage thickness with sprifermin 100 μg for the first 2 years; however, overall cartilage thickness reduced for both sprifermin 100 μg and placebo groups between years 2 and 3 but the significant difference between treatment groups was maintained. 70 Of note, no difference in symptom improvement was reported between treatment groups. This raises an important issue for potentially effective treatments improving OA structural pathologies: how long after changing structure will we need to follow patients in order to see a difference in patient important outcomes (such as reduction in symptoms or joint replacement)?
Wnt pathway inhibition. SM04690 is an inhibitor of the Wnt signalling pathway, a signal transduction pathway thought to play a role in cartilage degeneration and the pathogenesis of OA, through their effects on chondrocyte, osteoblast and synovial cell differentiation. 71, 72 Alterations in genes encoding Wnt signalling pathway proteins have been detected in murine and human OA tissues, along with lower levels of the Wnt inhibitory protein DKK1. 72 A phase II randomized, doubleblind, placebo-controlled trial comparing three doses of SM04690 (low, medium and high doses) in 455 patients with knee OA has recently been completed. A prespecified subpopulation of this group with unilateral symptomatic knee OA (n = 164) was also analysed, based on the hypothesis that patients with symptomatic OA in both knees may not respond as well as those with only one knee affected (a 'widespread pain' interference phenomenon). A further subpopulation, patients with unilateral knee OA without widespread pain (n = 128), was also analysed. Results have shown that in the intention-to-treat population, there was no significant difference in WOMAC A1 (pain on walking) improvement between treatment groups; however, patients receiving the medium dose (0.07 mg) SM04690 had significant improvement in their WOMAC A1 score compared with placebo in unilateral symptomatic knee patients at 39 and 52 weeks and unilateral symptomatic patients without widespread pain at 26, 39 and 52 weeks. 73 Interleukin-1α and β inhibition. In OA, IL-1α and IL-1β are expressed in increased levels within the cartilage and synovial membrane. 74, 75 Elevated IL-1 levels are associated with increased expression of markers of OA pathophysiology including catabolic enzymes, prostaglandins, nitric oxide and other markers in OA fluids and tissue. 76 In addition, blockage of the IL-1 receptor can slow the progression of OA in animal models. [77] [78] [79] [80] Anakinra is a recombinant form of an IL-1 receptor antagonist (IL-1Ra). A multicentre, doubleblind, placebo-controlled study randomized 170 patients to receive a single intra-articular injection of placebo, anakinra 50 mg, or anakinra 150 mg in their symptomatic knee. Although anakinra was well tolerated, no significant difference in the mean WOMAC pain score improvements from baseline to week 4 could be detected between the treatment groups. 81 Lutikizumab (formerly ABT-981) is a novel human dual variable domain immunoglobulin that binds and inhibits the actions of IL-1α and IL-1β. 82 A randomized, double-blind, placebo-controlled, parallel-group phase II trial (ILLUSTRATE-K) compared two-weekly SC injections of lutikizumab at 25 mg, 100 mg, or 200 mg in patients with knee OA for 50 weeks. 83 Preliminary results demonstrated significant improvement in WOMAC pain score at 16 weeks with lutikizumab 100 mg compared with placebo (achieving the primary endpoint); however, no significant improvement compared with placebo was demonstrated with lutikizumab 25 mg or 200 mg at 16 weeks. Cartilage thickness, MRI synovitis, and other structural endpoints were similar between lutikizumab and placebo, although lutikizumab was generally well tolerated. Given the lack of dose response and failure to meet structural endpoints, there is uncertainty regarding the clinical efficacy of lutikizumab from this trial.
Lutikizumab has also been trialled in patients with erosive hand OA. A phase IIa, placebo-controlled, randomized study measured clinical and radiological outcomes in 131 patients with hand OA as per American College of Rheumatology criteria (⩾3 inflamed interphalangeal joints which are tender, swollen, or both, hand pain ⩾6 (scale 0-10), and ⩾1 erosive interphalangeal joint on X-ray). Patients were given lutikizumab 200 mg (n = 67) or placebo (n = 64) every 2 weeks for 26 weeks. Preliminary data did not demonstrate a significant difference in Australian/Canadian Hand OA Index (AUSCAN) pain improvement scores between treatment groups at 16 weeks. In addition, there was no significant difference in X-Ray or MRI data between treatment groups. 84 The IL-1 story continues to be intriguing. Canakinumab is a monoclonal antibody targeting IL-1β. Previous in vitro work on human chondrocytes demonstrated increased proteoglycan and reduced nitric oxide synthesis which may result in reduced cartilage breakdown. 85 A recent very large randomized, placebo-controlled trial investigated the cardiovascular effect of subcutaneous canakinumab at doses 50 mg, 150 mg or 300 mg journals.sagepub.com/home/tab 7 every 3 months for a median of 3.7 years, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level ⩾2 mg/l on blood testing. 86 The results demonstrated canakinumab at a dose of 150 mg was associated with a significantly lower rate of recurrent cardiovascular events compared with placebo, independent of lipid-level lowering.
Although this was primarily a cardiovascular study, a substudy of this trial has recently reported there is also a reduced incidence of OA symptoms and total knee and hip replacements in the patients who received canakinumab. 87 Cathepsin K inhibition. Cathepsin K is a cysteine protease involved in bone resorption, degrading types I and II collagen and aggrecan found in cartilage. MIV-711 is a potent, selective and reversible inhibitor of cathepsin K which aims to prevent degradation of cartilage, thereby improving symptoms in OA. A 6-month, multicentre, randomized, placebo-controlled, double-blind, three-arm parallel, phase IIa study evaluating the efficacy, safety and tolerability of MIV-711 in patients with knee OA was completed in 2017 and preliminary results presented. 88 Patients with knee OA received MIV-711 100 mg, 200 mg or matched placebo four times daily for 26 weeks. A significant reduction in pain and QoL scores was not detected, although there was a trend towards a reduction in pain scores with 100 mg and 200 mg doses at 26 weeks. However, a unique aspect of this trial was the key secondary outcome of three-dimensional quantitative bone area and this novel imaging biomarker can potentially be used as an outcome measure in further DMOAD trials. 89 The results demonstrated a significant reduction in femoral OA bone disease progression on MRI at week 26 for MIV-711 100 mg and 200 mg doses versus placebo. There was also a significant reduction in the loss of cartilage thickness on the medial femur for 100 mg versus placebo. The main AEs reported were musculoskeletal symptoms, skin disorders and infections, but there was a reported overall acceptable safety profile. 90 Further studies are needed to evaluate the potential structure-modifying effects of this agent. 
Conclusion

